跳至主要内容
临床试验/NCT06299670
NCT06299670已完成4 期

Efficacy of Combination of Hdroxyurea and Thalidomide Over Either Hydroxyurea or Thalidomide Alone in the Treatment of Transfusion Dependent Thalassemia in Children: A Quasi-Randomised Clinical Trial

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh2 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2023年11月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
90
试验地点
2
主要终点
Change in Blood transfusion frequency

研究概览

简要总结

The goal of this clinical trial is to find out the efficacy of combined Hydroxyurea and thalidomide transfusion dependent thalassemia patients. The main objectives are to compare the level of Hb, Transfusion interval, serum ferritin level before & after treatment between single and combination of thalidomide and HU.

Researcher will compare the effectiveness of combined hydroxyurea and thalidomide and hydroxyurea and thalidomide alone. Participants will be divided in three groups:

Group I: will take combination of HU and Thalidomide. Group II: Will take HU alone and Group III: Will take Thalidomide alone and outcome will be recorded.

详细描述

Thalassemia is a monogenic hematological disorder caused as a result of defect in synthesis of globin chains of hemoglobin. It causes ineffective erythropoiesis & lysis of red blood cells due to relative excess of unaffected globin chain.

Annually about 50,000 children with a severe form of thalassemia (β-thalassemia major and HbE β-thalassemia) born globally among which 26,000 patients are regular blood transfusion dependent. About 70-75% patients are found in southeast asia & eastern mediterranean region.

Hematopoietic stem cell transplant (HSCT) is the only curative treatment option for homozygous thalassemia patients. Unfortunately its application is limited due to scarcity of HLA-matched donor, high cost , lack of specialized dedicated centers and risk of transplant related morbidity and mortality.

Regular blood transfusion is an essential life saving supportive care to maintain growth and development in children with severe β-thalassemia. However, Long term blood transfusion causes iron overload with cardiac, hepatic and endocrine coomplications , spread transfusion transmitted infections and formation of antibody. These limitations have compelled researchers to search for novel therapeutic modalities.

In recent years, induction of Fetal Hemoglobin (HbF) production pharmacologically is an promising treatment options for hemoglobinopathies. Different HbF inducing agents like Hydroxyurea (HU), Butyrate derivatives, Azacitidine, Decitabine, Tricostatin-A are shown to be effective in decreasing clinical severity and complications of TDT. HU induces a 2-9 fold increase in γ-globin gene and being used for decades in thalassemia treatment. But its utility is limited due to its mild and ill sustained therapeutic effect in HbF synthesis. Thalidomide, an immunomodulatory drug also shown to produce significant and persistent rise in Hb in few small studies and several case reports. It induces Gamma Globin gene expression by increasing reactive oxygen species-mediated p38 mitogen-activated protein kinase (MAPK) signaling and histone H4 acetylation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
3 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Patients diagnosed as transfusion dependent thalassemia
  • Age ranged from 3-18 years
  • Blood transfusion more than 1 year.
  • no bleeding disorder

排除标准

  • Active systemic co-morbidity,
  • Past personal or family history of thrombophilia,
  • Recent fracture or recent major surgery
  • Use of drugs that might affect Hb levels 15 days before enrollment

研究组 & 干预措施

Hydroxyurea

Experimental

Hydroxyurea

干预措施: Hydroxy Urea (Drug)

Thalidomide

Experimental

Patient getting Thalidomide

干预措施: Thalidomide (Drug)

Combination

Experimental

combination of Thalidomide & Hydroxyurea

干预措施: Combinations (Drug)

结局指标

主要结局

Change in Blood transfusion frequency

时间窗: 12 weeks after treatment initiation

Change in Blood transfusion frequency after 3 month

Change in Hb Level

时间窗: 12 weeks after treatment initiation

Change in Hb gm/dl after 3 month

Change in HbF

时间窗: 12 weeks after treatment initiation

Change in Hb F after 3 month

次要结局

  • Adverse effect(12 weeks from treatment initiation)
  • Change in Biochemicals(12 weeks after treatment initiation)

研究者

发起方
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
申办方类型
Other
责任方
Principal Investigator
主要研究者

MD ANWARUL KARIM

Professor

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

研究点 (2)

Loading locations...

相似试验